Abstract
SARS-CoV-2 surveillance is crucial to identify variants with altered epidemiological properties. Wastewater-based epidemiology (WBE) provides an unbiased and complementary approach to sequencing individual cases. Yet, national WBE surveillance programs have not been widely implemented and data analyses remain challenging.
We deep-sequenced 2,093 wastewater samples representing 95 municipal catchments, covering >57% of Austria’s population, from December 2020 to September 2021. Our Variant Quantification in Sewage pipeline designed for Robustness (VaQuERo) enabled us to deduce variant abundance from complex wastewater samples and delineate the spatiotemporal dynamics of the dominant Alpha and Delta variants as well as regional clusters of other variants of concern. These results were cross validated by epidemiological records of >130,000 individual cases. Finally, we provide a framework to predict emerging variants de novo and infer variant-specific reproduction numbers from wastewater.
This study demonstrates the power of national-scale WBE to support public health and promises particular value for countries without dense individual monitoring.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project was funded in part by the Austrian Agency for Health and Food Safety (AGES), the Vienna science and Technology Fund (WWTF) as part of the WWTF COVID-19 Rapid Response Funding 2020 (A.B.), the Austrian Science Fund (FWF1212P) and the Austrian Academy of Sciences. Access to WWTP and sample logistics was possible through the Coron-A Project, which was supported and funded by the Austrian Federal Ministry of Education, Science and Research, the Austrian Federal Ministry of Agriculture, Regions and Tourism, the Provincial Governments of Lower Austria, Upper Austria, Salzburg, Carinthia, Tyrol, Styria, Burgenland, Vorarlberg and the Austrian Association of Cities and Towns.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
A waiver of ethical approval was received from the deputy chair of the Ethics commission of the City of Vienna Dr. Tamchina.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
